东北制药连跌6天，南方基金旗下1只基金位列前十大股东

Group 1 - Northeast Pharmaceutical has experienced a continuous decline for six trading days, with a cumulative drop of -5.55% [1] - The company is a listed subsidiary of Liaoning Fangda Group Industrial Co., Ltd. [1] - Southern Fund's Southern CSI 1000 ETF is among the top ten shareholders of Northeast Pharmaceutical and has reduced its holdings in the first quarter of this year [1] Group 2 - The Southern CSI 1000 ETF has achieved a year-to-date return of 14.26%, ranking 765 out of 2930 in its category [2] - The fund's performance over different periods includes a 0.15% increase over the past week, 6.92% over the past month, and 14.29% over the past three months [2] - The average performance of similar funds is lower, with a year-to-date return of 10.14% [2] Group 3 - The fund manager of Southern CSI 1000 ETF is Ms. Cui Lei, who has a master's degree in financial engineering from Cornell University and holds multiple financial certifications [3][4] - Ms. Cui has extensive experience in fund management, having held various positions within Southern Fund since 2015 [3][4] - The Southern Fund Management Co., Ltd. was established in March 1998 and has several major shareholders, including Huatai Securities Co., Ltd. and Shenzhen Investment Holdings Co., Ltd. [4]